Yurong Wen

Dr. Yurong Wen


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2014 in Pathogens and Disease
Verified
Journal Article
Open access
PDF file
YWYurong Wen
Yurong Wen
EBEster Behiels
Ester Behiels
BDBart Devreese
Bart Devreese
The authors review how toxin/antitoxin systems are involved in regulation of bacterial metabolic activity and how they control the lifestyle of bacteria in rela

9 July 2020 in ACS Central Science
Verified
Journal Article
Closed access
YZYufeng Zhao
Yufeng Zhao
YSYi Shen
Yi Shen
YWYurong Wen
Yurong Wen
RCRobert Campbell
Robert Campbell

1 April 2013 in Structure
Verified
Journal Article
Closed access
JFJan Felix
Jan Felix
JEJonathan Elegheert
Jonathan Elegheert
IGIrina Gutsche
Irina Gutsche
ASAlexander V. Shkumatov
Alexander V. Shkumatov
YWYurong Wen
Yurong Wen
SSSavvas N. Savvides
Savvas N. Savvides

30 October 2014 in Nature Communications
Verified
Journal Article
Open access
JDJohan Desmet
Johan Desmet
KVKenneth Verstraete
Kenneth Verstraete
YBYehudi Bloch
Yehudi Bloch
ELEric Lorent
Eric Lorent
YWYurong Wen
Yurong Wen
SSSavvas N. Savvides
Savvas N. Savvides
Protein scaffolds can provide a promising alternative to antibodies for various biomedical and biotechnological applications, including therapeutics. Here we describe the design and development of the Alphabody, a protein scaffold featuring a single-chain antiparallel triple-helix coiled-coil fold. We report affinity-matured Alphabodies with favourable physicochemical properties that can specifically neutralize human interleukin (IL)-23, a pivotal therapeutic target in autoimmune inflammatory diseases such as psoriasis and multiple sclerosis. The crystal structure of human IL-23 in complex with an affinity-matured Alphabody reveals how the variable interhelical groove of the scaffold uniquely targets a large epitope on the p19 subunit of IL-23 to harness fully the hydrophobic and hydrogen-bonding potential of tryptophan and tyrosine residues contributed by p19 and the Alphabody, respectively. Thus, Alphabodies are suitable for targeting protein–protein interfaces of therapeutic importance and can be tailored to interrogate desired design and binding-mode principles via efficient selection and affinity-maturation strategies.

21 August 2024 in Immunological Reviews
Verified
Journal Article
Open access
TYTing Yu
Ting Yu
FZFang Zheng
Fang Zheng
WHWenbo He
Wenbo He
SMSerge Muyldermans
Serge Muyldermans
YWYurong Wen
Yurong Wen
Summary: Heavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen‐binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines.

23 July 2014 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
YWYurong Wen
Yurong Wen
EBEster Behiels
Ester Behiels
JFJan Felix
Jan Felix
JEJonathan Elegheert
Jonathan Elegheert
BVBjorn Vergauwen
Bjorn Vergauwen
SSSavvas N. Savvides
Savvas N. Savvides
Nearly all bacteria exhibit a type of phenotypic growth described as persistence that is thought to underlie antibiotic tolerance and recalcitrant chronic infections. The chromosomally encoded high-persistence (Hip) toxin–antitoxin proteins HipASO and HipBSO from Shewanella oneidensis, a proteobacterium with unusual respiratory capacities, constitute a type II toxin–antitoxin protein module. Here we show that phosphorylated HipASO can engage in an unexpected ternary complex with HipBSO and double-stranded operator DNA that is distinct from the prototypical counterpart complex from Escherichia coli. The structure of HipBSO in complex with operator DNA reveals a flexible C-terminus that is sequestered by HipASO in the ternary complex, indicative of its role in binding HipASO to abolish its function in persistence. The structure of HipASO in complex with a non-hydrolyzable ATP analogue shows that HipASO autophosphorylation is coupled to an unusual conformational change of its phosphorylation loop. However, HipASO is unable to phosphorylate the translation factor Elongation factor Tu, contrary to previous reports, but in agreement with more recent findings. Our studies suggest that the phosphorylation state of HipA is an important factor in persistence and that the structural and mechanistic diversity of HipAB modules as regulatory factors in bacterial persistence is broader than previously thought.